SMT202000345T1 - Metodo di trattamento e composizioni comprendenti un doppio inibitore di pi3k delta-gamma chinasi e un corticosteroide - Google Patents

Metodo di trattamento e composizioni comprendenti un doppio inibitore di pi3k delta-gamma chinasi e un corticosteroide

Info

Publication number: SMT202000345T1
Authority: SM; San Marino
Prior art keywords: corticosteroid; compositions; treatment; kinase inhibitor; pi3k delta
Prior art date: 2014-09-03

Application number

SM20200345T

Other languages

English (en)

Inventor

Srikant Viswanadha

Venkata Satya Vakkalanka Swaroop Kumar

Original Assignee

Rhizen Pharmaceuticals S A

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-09-03

Filing date

2015-09-03

Publication date

2020-07-08

2015-09-03 Application filed by Rhizen Pharmaceuticals S A filed Critical Rhizen Pharmaceuticals S A

2020-07-08 Publication of SMT202000345T1 publication Critical patent/SMT202000345T1/it

Links

239000003246 corticosteroid Substances 0.000 title 1
230000009977 dual effect Effects 0.000 title 1
229940043355 kinase inhibitor Drugs 0.000 title 1
239000000203 mixture Substances 0.000 title 1
239000003757 phosphotransferase inhibitor Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Immunology (AREA)
Pulmonology (AREA)
Physical Education & Sports Medicine (AREA)
Diabetes (AREA)
Orthopedic Medicine & Surgery (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Neurology (AREA)
Endocrinology (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Transplantation (AREA)
Vascular Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Cardiology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Neurosurgery (AREA)
Ophthalmology & Optometry (AREA)
Heart & Thoracic Surgery (AREA)
Otolaryngology (AREA)
Gynecology & Obstetrics (AREA)
Reproductive Health (AREA)

SM20200345T 2014-09-03 2015-09-03 Metodo di trattamento e composizioni comprendenti un doppio inibitore di pi3k delta-gamma chinasi e un corticosteroide SMT202000345T1 (it)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
IN4287CH2014		2014-09-03
EP15774713.0A EP3188759B1 (en)	2014-09-03	2015-09-03	Method of treatment and compositions comprising a dual pi3k delta-gamma kinase inhibitor and a corticosteroid
PCT/IB2015/056720 WO2016035032A1 (en)	2014-09-03	2015-09-03	Method of treatment and compositions comprising a dual pi3k delta-gamma kinase inhibitor and a corticosteroid

Publications (1)

Publication Number	Publication Date
SMT202000345T1 true SMT202000345T1 (it)	2020-07-08

Family

ID=54249540

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SM20200345T SMT202000345T1 (it)	2014-09-03	2015-09-03	Metodo di trattamento e composizioni comprendenti un doppio inibitore di pi3k delta-gamma chinasi e un corticosteroide

Country Status (26)

Country	Link
US (2)	US10786504B2 (it)
EP (2)	EP3701950A1 (it)
JP (3)	JP6559775B2 (it)
KR (1)	KR20170044203A (it)
CN (2)	CN113332439A (it)
AU (2)	AU2015310545B2 (it)
BR (1)	BR112017004163A2 (it)
CA (1)	CA2958988A1 (it)
CL (1)	CL2017000512A1 (it)
CY (1)	CY1123075T1 (it)
DK (1)	DK3188759T3 (it)
EA (2)	EA038527B1 (it)
ES (1)	ES2802202T3 (it)
HR (1)	HRP20200968T1 (it)
HU (1)	HUE049480T2 (it)
IL (2)	IL250918B (it)
LT (1)	LT3188759T (it)
MX (2)	MX376875B (it)
PH (1)	PH12017500378A1 (it)
PL (1)	PL3188759T3 (it)
PT (1)	PT3188759T (it)
RS (1)	RS60450B1 (it)
SG (2)	SG10202100596SA (it)
SI (1)	SI3188759T1 (it)
SM (1)	SMT202000345T1 (it)
WO (1)	WO2016035032A1 (it)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN113557020A (zh) *	2018-09-14	2021-10-26	瑞真药业公司	包含crac抑制剂和皮质类固醇的组合物及其使用方法
CN114206332B (zh)	2019-06-04	2024-08-23	艾库斯生物科学有限公司	2,3,5-三取代吡唑并[1,5-a]嘧啶化合物
CN116492351B (zh) *	2023-03-13	2024-03-12	香港大学深圳医院	氯替泼诺在制备治疗早发性卵巢功能不全及卵巢响应匮乏药物中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4018774A (en)	1976-02-13	1977-04-19	E. R. Squibb & Sons, Inc.	Steroidal [16α,17-d]isoxazolidines
SE8106165L (sv)	1981-10-19	1983-04-20	Atlas Copco Ab	Forfarande for bergbultning och bergbult
GB0415747D0 (en)	2004-07-14	2004-08-18	Novartis Ag	Organic compounds
CA2711558C (en)	2008-01-04	2016-12-13	Intellikine, Inc.	Phosphatidyl inositol-3 kinase inhibiting compounds
US8193182B2 (en)	2008-01-04	2012-06-05	Intellikine, Inc.	Substituted isoquinolin-1(2H)-ones, and methods of use thereof
US11058699B2 (en)	2008-07-01	2021-07-13	Wisconsin Alumni Research Foundation	Method and compositions for inhibition of double stranded DNA viruses
CN102481282A (zh) *	2009-03-24	2012-05-30	新加坡国立大学	青蒿素衍生物用于治疗哮喘和慢性阻塞性肺病(copd)的用途
EP2993178A1 (en)	2009-09-11	2016-03-09	CHIESI FARMACEUTICI S.p.A.	Glucocorticoid condensed in position 16,17 with an isoxazolidine group
SG10201500895XA (en)	2009-11-05	2015-04-29	Rhizen Pharmaceuticals Sa	Chromen-4-one Derivatives As Kinase Modulators
EP2528607A4 (en) *	2010-01-28	2014-07-16	Univ Johns Hopkins	COMPOSITIONS AND METHODS FOR REVERSING A CORTICOSTEROID RESISTANCE OR TREATING RESPIRATORY RESPONSE
EP3689364A1 (en) *	2010-02-08	2020-08-05	Shenzhen Evergreen Therapeutics Co., Ltd.	Methods for the use of progestogen as a glucocorticoid sensitizer
AU2012205669B2 (en)	2011-01-10	2015-08-20	Infinity Pharmaceuticals Inc.	Processes for preparing isoquinolinones and solid forms of isoquinolinones
UA113508C2 (xx)	2011-03-15	2017-02-10		Ізоксазолідинові похідні
RS58326B1 (sr)	2011-05-04	2019-03-29	Rhizen Pharmaceuticals S A	Nova jedinjenja kao modulatori proteinskih kinaza
CA2872252C (en)	2012-05-22	2019-06-18	Atlas Copco Canada Inc.	Rock bolt and method of installing a rock bolt
WO2014072937A1 (en) *	2012-11-08	2014-05-15	Rhizen Pharmaceuticals Sa	Pharmaceutical compositions containing a pde4 inhibitor and a pi3 delta or dual pi3 delta-gamma kinase inhibitor
CN204282361U (zh)	2014-12-11	2015-04-22	湖南科技大学	一种带钢丝网的软土地基充气锚杆

2015
- 2015-09-03 SG SG10202100596SA patent/SG10202100596SA/en unknown
- 2015-09-03 SI SI201531258T patent/SI3188759T1/sl unknown
- 2015-09-03 SG SG11201701499YA patent/SG11201701499YA/en unknown
- 2015-09-03 JP JP2017512375A patent/JP6559775B2/ja not_active Expired - Fee Related
- 2015-09-03 ES ES15774713T patent/ES2802202T3/es active Active
- 2015-09-03 PT PT157747130T patent/PT3188759T/pt unknown
- 2015-09-03 DK DK15774713.0T patent/DK3188759T3/da active
- 2015-09-03 AU AU2015310545A patent/AU2015310545B2/en not_active Ceased
- 2015-09-03 PL PL15774713T patent/PL3188759T3/pl unknown
- 2015-09-03 CN CN202110658421.3A patent/CN113332439A/zh active Pending
- 2015-09-03 EA EA201790379A patent/EA038527B1/ru unknown
- 2015-09-03 KR KR1020177008971A patent/KR20170044203A/ko not_active Ceased
- 2015-09-03 LT LTEP15774713.0T patent/LT3188759T/lt unknown
- 2015-09-03 US US15/508,429 patent/US10786504B2/en not_active Expired - Fee Related
- 2015-09-03 SM SM20200345T patent/SMT202000345T1/it unknown
- 2015-09-03 RS RS20200736A patent/RS60450B1/sr unknown
- 2015-09-03 HU HUE15774713A patent/HUE049480T2/hu unknown
- 2015-09-03 CN CN201580052216.5A patent/CN106714842B/zh not_active Expired - Fee Related
- 2015-09-03 EP EP20166664.1A patent/EP3701950A1/en not_active Withdrawn
- 2015-09-03 EP EP15774713.0A patent/EP3188759B1/en active Active
- 2015-09-03 MX MX2017002878A patent/MX376875B/es active IP Right Grant
- 2015-09-03 EA EA202092492A patent/EA202092492A1/ru unknown
- 2015-09-03 WO PCT/IB2015/056720 patent/WO2016035032A1/en not_active Ceased
- 2015-09-03 BR BR112017004163A patent/BR112017004163A2/pt not_active Application Discontinuation
- 2015-09-03 CA CA2958988A patent/CA2958988A1/en not_active Abandoned
- 2015-09-03 HR HRP20200968TT patent/HRP20200968T1/hr unknown
2017
- 2017-02-28 PH PH12017500378A patent/PH12017500378A1/en unknown
- 2017-03-02 IL IL250918A patent/IL250918B/en active IP Right Grant
- 2017-03-03 MX MX2020011472A patent/MX2020011472A/es unknown
- 2017-03-03 CL CL2017000512A patent/CL2017000512A1/es unknown
2019
- 2019-07-17 JP JP2019131860A patent/JP2019172708A/ja active Pending
2020
- 2020-06-23 CY CY20201100575T patent/CY1123075T1/el unknown
- 2020-08-21 US US16/999,825 patent/US20210030757A1/en not_active Abandoned
2021
- 2021-01-06 AU AU2021200051A patent/AU2021200051A1/en not_active Abandoned
- 2021-02-07 IL IL280686A patent/IL280686A/en unknown
- 2021-09-24 JP JP2021155711A patent/JP2021191804A/ja active Pending

Also Published As

Publication number	Publication date
CL2017000512A1 (es)	2017-11-03
HUE049480T2 (hu)	2020-09-28
HRP20200968T1 (hr)	2020-10-16
SG11201701499YA (en)	2017-03-30
US10786504B2 (en)	2020-09-29
KR20170044203A (ko)	2017-04-24
JP2021191804A (ja)	2021-12-16
SI3188759T1 (sl)	2020-08-31
JP2019172708A (ja)	2019-10-10
US20170281630A1 (en)	2017-10-05
CN113332439A (zh)	2021-09-03
EP3188759A1 (en)	2017-07-12
LT3188759T (lt)	2020-07-10
EA202092492A1 (ru)	2021-07-30
EP3188759B1 (en)	2020-04-01
AU2015310545B2 (en)	2020-10-22
PT3188759T (pt)	2020-07-02
EA038527B1 (ru)	2021-09-10
MX2017002878A (es)	2017-05-30
MX376875B (es)	2025-03-07
RS60450B1 (sr)	2020-07-31
NZ729419A (en)	2021-08-27
DK3188759T3 (da)	2020-06-29
AU2021200051A1 (en)	2021-02-18
JP6559775B2 (ja)	2019-08-14
EP3701950A1 (en)	2020-09-02
IL250918B (en)	2021-02-28
MX2020011472A (es)	2020-12-07
AU2015310545A1 (en)	2017-03-16
CA2958988A1 (en)	2016-03-10
EA201790379A1 (ru)	2017-06-30
CN106714842B (zh)	2021-07-02
IL250918A0 (en)	2017-04-30
PH12017500378A1 (en)	2017-07-17
WO2016035032A1 (en)	2016-03-10
CY1123075T1 (el)	2021-10-29
JP2017525739A (ja)	2017-09-07
ES2802202T3 (es)	2021-01-15
PL3188759T3 (pl)	2020-11-02
US20210030757A1 (en)	2021-02-04
SG10202100596SA (en)	2021-02-25
CN106714842A (zh)	2017-05-24
IL280686A (en)	2021-03-25
BR112017004163A2 (pt)	2017-12-05

Publication	Publication Date	Title
SG11201706917WA (en)	2017-09-28	Salts of pi3k inhibitor and processes for their preparation
IL259801A (en)	2018-07-31	ezh2 inhibitors and methods of using them
IL247102A0 (en)	2016-09-29	Combination of pd-1 antagonist and ido1 inhibitor for cancer treatment
EP3233846A4 (en)	2018-07-18	Inhibitors of bromodomains
IL257061A (en)	2018-03-29	Inhibitors of ezh2
IL259796A (en)	2018-07-31	Aza-benzimidazole inhibitors of pad4
EP3105327A4 (en)	2017-10-18	Compositions and methods of using microrna inhibitors
GB201521059D0 (en)	2016-01-13	Inhibitors of metallo-beta-lactamases
AP2016009661A0 (en)	2016-12-31	Quinolizinone derivatives as pi3k inhibitors
IL280686A (en)	2021-03-25	Method and compounds containing a dual PI3K inhibitor and steroid
ZA201705530B (en)	2018-05-30	6-morpholinyl-2-pyrazolyl-9h-purine derivatives and their use as pi3k inhibitors
IL252752A0 (en)	2017-08-31	Pharmaceutical preparations containing a combination of pyridazine and egfr inhibitor